Global Licensing Partnering Terms & Agreements,Case Studies,Leading Life Science

Posted by Deevika on April 3rd, 2019

The global market status for Licensing Partnering Terms & Agreements in Pharma, Biotech is precisely examined through a smart research report added to the broad database managed by Market Research Hub (MRH). This study is titled “Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2014-2019”, which tends to deliver in-depth knowledge associated to the Licensing Partnering Deal for the Current Agreements deals and alliances database., In addition, a comprehensive appendix is provided organized . This report provides everything a prospective dealmaker needs to know about licensing partnering in the research and commercialization of technologies

Get Sample Copy of this Report@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2222641

The Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014- 2019 report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the world’s leading life science companies.

This report provides details of the latest licensing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of licensing agreements from 2014 to 2019.

There has been a long standing willingness for parties to enter licensing deals. Such deals enable both parties to benefit from the upside of a big R&D win, whilst mitigating the risks of going it alone in the risky preclinical and clinical development stages.

Licensing is a specific type of partnering deal whereby the parties to the deal agree to commercialize a compound, product or technology.

Specifically, licensing is the granting of permission to use intellectual property rights, such as trademarks, patents, or technology, under defined conditions

there are several forms of licensing deal. Traditional licensing arrangement whereby an owner of intellectual property (the licensor) provides access to its technology to another company (the licensee) in return for agreed payments and royalties on subsequent sales of product(s) derived from the intellectual property.

In more recent times, licensing is often the outcome of a successful period of collaboration on the research and development of a technology or compound, resulting in a product which can be commercialized. In this situation, the licensing agreement governs who has permission to commercialize and what payments are due should commercialization proceed.

Other forms of licensing such as sub-licensing and cross-licensing are also explored, with examples provided together with listing of recent deals in pharma, biotech and diagnostics.

The report provides a detailed understand and analysis of how and why companies enter licensing deals. The majority of deals are multicomponent whereby the licensee retains either a right or option to license to commercialize the resultant product of the research collaboration. There are also numerous pure licensing deals whereby the products originator takes on a development/commercialization partner in order to maximize a technologies/products prospects.

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all licensing deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms were available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of licensing deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in licensing as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of licensing deals. The chapter includes numerous case studies to enable understanding of both pure licensing deals and multicomponent deals where collaborative R&D forms a part.

Chapter 4 provides a review of the leading licensing deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a review of the top 50 most active biopharma companies in licensing. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

 Request Report TOC @ https://www.marketresearchhub.com/report/global-licensing-partnering-terms-and-agreements-in-pharma-biotech-and-diagnostics-2014-2019-report.html

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in licensing deal making
2.1. Introduction
2.2. Definition of licensing deals
2.3. Success factors for licensing deals
2.4. When licensing can be useful
2.5. Attributes of licensing deals
2.6. Trends in licensing deals since 2014
2.6.1. Licensing deal making by year since 2014
2.6.2. Licensing deal making by phase of development since 2014
2.6.3. Licensing deal making by industry sector since 2014
2.6.4. Licensing deal making by therapy area since 2014
2.6.5. Licensing deal making by technology type since 2014
2.6.6. Licensing deal making by most active company since 2014
2.7. Option to license
2.8. Adding co-promotion to the mix
2.9. The future of licensing deals

Chapter 3 Overview of licensing deal structure
3.1. Introduction
3.2. Pure versus multi-component licensing deals
3.3. Pure licensing agreement structure
3.3.1. Example licensing agreements
3.3.1.a. Case study 1: Ignyta Nerviano Medical Sciences
3.3.1.b. Case study 2: Sanofi - Pozen
3.4. Licensing rights as part of a wider alliance agreement
3.4.1. Example licensing clauses
3.4.1.a. Case study 3: 4D Molecular Therapeutics UniQure
3.4.1.b. Case study 4: Kyowa Hakko Kirin Ultragenyx Pharmaceuticals
3.4.2. Example licensing option right clauses
3.4.2.a. Case study 5: Forest Laboratories - Trevena
3.4.2.b. Case study 6: Abbvie Receptos

Chapter 4 Leading licensing deals
4.1. Introduction
4.2. Top licensing deals by value

Chapter 5 Top 50 most active licensing dealmakers
5.1. Introduction
5.2. Top 50 most active licensing dealmakers

Continued………..@@

                              

Also See: Licensing Deals, Licensing Deal, Since 20142, Licensing Partnering, Terms, Since, Report
Link To Directory
Top Searches - Trending Searches - New Articles - Top Articles - Trending Articles - Featured Articles - Top Members

Copyright 2019 Uberant.com
531,791 total articles and counting.